
    
      PRIMARY OBJECTIVE:

      I. To evaluate the rate of major pathologic response (MPR).

      OUTLINE:

      Patients receive bintrafusp alfa intravenously (IV) on days 1, 15, and 29 in the absence of
      unacceptable toxicity. Within 4-6 weeks after last dose of bintrafusp alfa, patients undergo
      surgery at the discretion of the treating surgeon. Within 8 weeks after surgery, patients may
      receive chemotherapy or undergo radiation therapy at the discretion of the treating
      physician.

      After completion of study treatment, patients are followed for up to 5 years.
    
  